Summarized by Masters of Longevity from PR Newswire.
A biotech press release about company leadership and clinical rollout plans for a proteomics-based blood test for earlier breast cancer risk stratification. It previews what readers will learn about clinical integration and nationwide scaling.
Key Takeaways
- Astrin's Certitude Breast is a non-imaging blood test that analyzes over 9,000 proteins to detect early-stage breast cancer.
- Certitude is intended as an adjunct risk-stratification tool after screening mammography, especially for women with dense breast tissue or high-risk profiles.
